NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Recommendation of “Buy” from Brokerages

Shares of NewAmsterdam Pharma (NASDAQ:NAMS) have been given a consensus recommendation of “Buy” by the six analysts that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $43.33.

A number of brokerages recently weighed in on NAMS. Scotiabank raised their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a report on Monday, March 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Finally, Needham & Company LLC decreased their price target on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th.

Insider Transactions at NewAmsterdam Pharma

In other news, major shareholder Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $25.39, for a total value of $4,215,019.29. Following the sale, the insider now directly owns 11,150,461 shares in the company, valued at approximately $283,110,204.79. This trade represents a 1.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James N. Topper purchased 4,005 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average price of $21.02 per share, for a total transaction of $84,185.10. Following the completion of the transaction, the director now directly owns 3,012,434 shares of the company’s stock, valued at $63,321,362.68. This represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 554,927 shares of company stock worth $13,446,287. 19.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds have recently made changes to their positions in NAMS. TimesSquare Capital Management LLC boosted its position in shares of NewAmsterdam Pharma by 3.7% during the third quarter. TimesSquare Capital Management LLC now owns 255,245 shares of the company’s stock valued at $4,237,000 after purchasing an additional 9,160 shares in the last quarter. Lisanti Capital Growth LLC bought a new position in NewAmsterdam Pharma in the third quarter valued at about $700,000. GSA Capital Partners LLP lifted its holdings in NewAmsterdam Pharma by 79.9% in the third quarter. GSA Capital Partners LLP now owns 66,402 shares of the company’s stock valued at $1,102,000 after acquiring an additional 29,496 shares during the period. Jennison Associates LLC lifted its holdings in NewAmsterdam Pharma by 8.9% in the third quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock valued at $16,937,000 after acquiring an additional 83,115 shares during the period. Finally, HealthInvest Partners AB lifted its holdings in NewAmsterdam Pharma by 83.4% in the third quarter. HealthInvest Partners AB now owns 138,983 shares of the company’s stock valued at $2,307,000 after acquiring an additional 63,189 shares during the period. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Trading Down 1.8 %

Shares of NAMS opened at $23.37 on Tuesday. The company has a market cap of $2.16 billion, a PE ratio of -8.99 and a beta of -0.04. The stock has a 50-day moving average price of $22.16 and a 200-day moving average price of $20.59. NewAmsterdam Pharma has a 12-month low of $15.19 and a 12-month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analysts’ expectations of $3.30 million. As a group, analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.